Goldenheim
Paul Goldenheim, Wilton, CT US
Patent application number | Description | Published |
---|---|---|
20100209514 | Method of treating pain by administering 24 hour oral oploid formulations exhibiting rapid rate of initial rise of plasma drug level - Patients are treated with 24-hour oral sustained release opioid formulations which, upon administration, provide an initially rapid opioid absorption such that the minimum effective analgesic concentration of the opioid is more quickly achieved. These sustained release opioid formulations include an effective amount of at least one retardant material to cause said opioid analgesic to be released at a such a rate as to provide an analgesic effect after oral administration to a human patient for at least about 24 hours, and are characterized by providing an absorption half-life from 1 to about 8 hours. A method of titrating a human patient utilizing these sustained release opioid formulations is also disclosed. | 08-19-2010 |
Paul Goldenheim, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20120191068 | Methods for Sustained Treatment of Bladder Pain and Irritative Voiding - Method are provided for treating a patient having bladder pain and/or irritative voiding symptoms. The method includes administering to the patient's bladder lidocaine or another anesthetic agent continuously over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect which is sustained beyond the end of the treatment period. | 07-26-2012 |
Paul D. Goldenheim, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20140073663 | METHOD OF PROVIDING SUSTAINED ANALGESIA WITH BUPRENORPHINE - A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval. | 03-13-2014 |